The development of cellular high-throughput compound screening assays that are highly predictive of a therapeutic's possible clinical success remains a critical challenge in target validation and discovery. This collaborative project will build and validate high-throughput assays relevant to type 2 diabetes (T2D) in human adipocytes. These assays will be calibrated by integrating evidence from genetic studies of human T2D. The goals of the collaboration are to:
- Build assays that read out T2D-relevant functions in human adipocytes.
- Deploy these assays to identify genes critical to these functions.
- Integrate the resulting data with clinical sequencing databases to identify mutations that protect individuals from T2D.
The ultimate purpose of this program is to identify new drug targets for T2D.